Metastatic Squamous Neck Cancer With Occult Primary - 14 Studies Found
| Recruiting |
: SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes : Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma : 2015-12-07 : Drug: SF1126 |
| Completed |
: Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer :
|
| Active, not recruiting |
: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer :
|
| Completed |
: Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab :
|
| Terminated |
: Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck :
|
| Completed |
: S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer :
|
| Active, not recruiting |
: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer :
|
| Completed |
: Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer :
|
| Completed |
: Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer :
|